

Supplementary Materials

HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation

Malte Roerden, Annika Nelde, Jonas S. Heitmann, Reinhild Klein, Hans-Georg Rammensee, Wolfgang A. Bethge and Juliane S. Walz




Figure S1. Subgroup analyses, cumulative relapse incidence and GvH frequency. (a,b) Kaplan-Meier analysis of OS in subgroups with regard to donor type. (c) Analysis of cumulative incidence of relapse (treating non-relapse mortality as a competing risk). (d) Overall frequency of acute and chronic GvH

depending on HED^{total} . (e) Kaplan-Meier analysis of OS for patients undergoing haploidentical HSCT. Abbreviations: GvH indicates Graft-versus-Host disease; HED, HLA evolutionary divergence; HSCT, hematopoietic stem cell transplantation; OS, overall survival; and #, only considering patients with OS > 3 months.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).